News Center

Cosmetics with KX-826 as the core ingredient launched for sale

Release time：2024-07-10 00:00

Beijing, July 10, 2024, Pioneering Pharmaceuticals (stock code: 9939.HK), announced that after its self-developed KX-826 was awarded the International Named Cosmetic Ingredient (INCI) designation, the cosmetic products with KX-826 as the main ingredient have been officially launched for sale globally in the recent days, and the first product is the topical anti-baldness solution targeting at androgenic alopecia (AGA).

 

The Company will further explore the use effect of KX-826 in the field of AGA and acne, actively enrich the product line and increase the promotion to target users to meet the needs of users in different use scenarios. The Company believes that the launch and sale of the new products will bring stable revenue and cash flow to the Group, which will bring long-term benefits to the Group as a whole.

 

KX-826 is one of the Group's core innovative products. In the course of its development, it has completed a number of clinical trials in the PRC and the United States for the treatment of AGA for both men and women, and has demonstrated excellent safety and efficacy in hair loss prevention and regrowth.

 

Dr. Tong Youzhi, Founder, Chairman and Chief Executive Officer of Pioneering Pharmaceuticals, said, “The launch of the new product is the first commercialization attempt of KX-826 in the field of dermatology, which marks the transition from the research and development stage to the commercialization stage. After the launch and sale, the Company will further promote the commercialization of its cosmetic products globally to provide more convenient and effective product choices for consumers in need of hair loss prevention and regrowth, and plans to allocate more resources in the future to enhance the Group's commercialization capabilities in order to improve brand awareness, capture market dynamics and increase product penetration.”

Previous:

Starting Again! Pioneer Pharmaceuticals KX-826 Tincture Registrational Clinical Trial Investigators Meeting Successfully Held

Next:

KX-826 Androgen receptor antagonist

recommend News

Kintor